Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal International Journal of Health, Engineering and Technology
Oktavia Nanda lestari
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Chemical Engineering, Chemistry & Bioengineering Dentistry Engineering Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Mechanical Engineering Medicine & Pharmacology Nursing Public Health Veterinary

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Design Of New Compounds Derived From Rosella Flavonoids As Diabetes Mellitus Enzyme Inhibitors Using Computer-Aided Drug Design Strategy Oktavia Nanda lestari; Tiara Ajeng Litsyani; Septian Maulid Wicahyo
International Journal of Health Engineering and Technology Vol. 4 No. 6 (2026): IJHET MARCH 2026
Publisher : CV. AFDIFAL MAJU BERKAH

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55227/ijhet.v4i6.603

Abstract

Type 2 diabetes mellitus is increasing rapidly in Indonesia with a projected prevalence of 16.09% in 2045, requiring local plant-based α-amylase and α-glucosidase enzyme inhibitors such as the flavonoid kaempferol-3-O-rutinoside from roselle flowers (Hibiscus sabdariffa L.), which shows potential in silico inhibition but suboptimal ADMETox profile. This in silico computational experimental study aims to design kaempferol-3-O-rutinoside derivative compounds as effective inhibitors through computer-aided drug design, with a population of parent compounds, target enzymes, and acarbose as controls; purposive samples in the form of substituent modifications; PyRx-AutoDock Vina, SwissADME, Toxtree instruments; and molecular docking analysis techniques (ΔG, RMSD) and ADMETox prediction. The results showed a new compound with ΔGbind -5.0 kcal/mol (α-amylase, RMSD 1.538), -5.2 kcal/mol (α-glucosidase, RMSD 2.08), similarity of residues Asn A 570, Asp A 243, Val A 867, high GI absorption (molecular weight 340.41 g/mol, LogP 0.06), and low class I toxicity. In conclusion, the new compound has the potential as a safe oral antidiabetic drug candidate, in vitro/in vivo validation is recommended for further development
Co-Authors Septian Maulid Wicahyo Tiara Ajeng Litsyani